Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 2/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.44 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2393680 | 1.00 | GABRA5 (0.44) | GABRA5GPR119GPR183GABRA1KCNH2 | |
| SCHEMBL2391515 | 0.89 | GABRA5 (0.45) | GABRA5GPR119GABRA1KCNH2DRD2 | |
| SCHEMBL2392624 | 0.87 | GPR119 (0.47) | GPR119GPR183KCNH2RAB9A | |
| SCHEMBL2392621 | 0.87 | GPR119 (0.47) | GPR119GPR183KCNH2RAB9A | |
| SCHEMBL1713423 | 0.86 | GPR119 (0.46) | GABRA5GPR119GPR183KCNH2DRD2 | |
| SCHEMBL1713347 | 0.85 | GPR119 (0.45) | GABRA5GPR119GPR183KCNH2 | |
| SCHEMBL1713350 | 0.85 | GPR119 (0.45) | GABRA5GPR119GPR183KCNH2 | |
| SCHEMBL2397230 | 0.85 | GPR119 (0.51) | GPR119GPR183KCNH2RAB9A | |
| SCHEMBL2397233 | 0.85 | GPR119 (0.51) | GPR119GPR183KCNH2RAB9A | |
| SCHEMBL1713018 | 0.85 | GPR119 (0.47) | GPR119GPR183KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321308-B9 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-08-08 | — | — | EP | claimed |
| EP-2321308-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-05-09 | — | — | EP | claimed |
| EP-2321308-B9 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-08-08 | — | — | EP | disclosed |
| EP-2321308-B1 | PIPERIDINE GPCR AGONISTS | PROSIDION LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20110230507-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-22 | — | — | US | disclosed |
| US-20110230507-A1 | Piperidine GPCR Agonists | PROSIDION LIMITED (GB) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230507-A1 | Piperidine GPCR Agonists | GPR119, GPR27, GLP1R | GABRA5 195/4885GPR119 1/4885GPR183 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.